ArticleERJ open research2026
Characteristics and asthma control status in the Korean Severe Asthma Registry-2: a real-world analysis.
Article in ERJ open research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Impact of Health Insurance Type on Access to Biologics and Systemic Corticosteroid Exposure in Patients With Severe Asthma: A Real-World Study From the Korean Severe Asthma Registry (KoSAR).Allergy, asthma & immunology research · 2026Article
- Expanding Horizons in Severe Asthma: Anti-IgE Biosimilars and the Redefinition of Patient Selection.Allergy, asthma & immunology research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe asthma is associated with poor asthma control, leading to poor outcomes. However, few studies have evaluated asthma control status in patients with severe asthma in the biologic era. This study aimed to evaluate baseline asthma control in patients with severe asthma using phase 2 of the Korean Severe Asthma Registry (KoSAR-2). Methods: Adult subjects meeting the international consensus definition of severe asthma were prospectively enrolled from 41 hospitals in Korea (March 2022 to June 2023). Data on demographics, comorbidities, lung function, inflammation and healthcare utilisation were collected. Using asthma control test (ACT) scores, patients were classified into a well-controlled asthma group (ACT ≥20) and poorly controlled asthma group (ACT <20). Results: Among 594 severe asthma patients, 51.9% had poorly controlled asthma. Multivariable analysis showed that medical aid (adjusted odds ratio (aOR)=5.515, 95% confidence interval (CI) 2.614-13.110, p<0.001), being underweight (aOR=4.129, 95% CI 1.081-20.192), forced expiratory volume in 1 s <60% predicted (aOR=1.854, 95% CI 1.090-3.175) and prior exacerbations (aOR=3.400, 95% CI 1.987-6.012) were associated with poorly controlled asthma, while T2 inflammation was associated with well-controlled asthma (aOR=0.560, 95% CI 0.316-0.977). However, biologic use was not associated with asthma control status. Conclusions: About half of patients with severe asthma in KoSAR-2 had poorly controlled asthma at baseline. While poor socioeconomic status reflected by medical aid was a key factor underlying poor asthma control, T2 inflammation was associated with better asthma control in severe asthma. These findings underscore the importance of both clinical management and socioeconomic support to improve asthma control outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.